Ivelin Georgiev Archives
NIH grant launches C. diff vaccine research initiative
Mar. 30, 2023—Vanderbilt has received an NIH grant to launch the Vanderbilt Antibody and Antigen Discovery for Clostridioides difficile Vaccines, or VANDy-CdV.
Discovery of “cross-reactive” antibodies could aid treatment of viral co-infections
Feb. 2, 2023— by Bill Snyder More than a million people in the United States are living with HIV, the virus that causes AIDS. One-fifth of them have been co-infected by the hepatitis C virus (HCV), which attacks the liver. Curative drugs for HCV are available, but many people don’t know they’ve been infected. And if they...
Antibody “fingerprinting” method potential advance to slow spread of dengue
Jan. 12, 2023—Vanderbilt researchers have reported a major advance in understanding and potentially preventing dengue, a devastating, mosquito-borne tropical viral infection that is spreading across the globe.
Vanderbilt team tracks cellular and antibody responses to COVID-19 vaccine
Jul. 20, 2022—In a technical tour de force, a collaborative team of Vanderbilt researchers has characterized the antigen-specific immune response to the Pfizer SARS-CoV-2 RNA vaccine.
Grant set to support Georgiev’s research to identify new antibodies
Mar. 24, 2022—Vanderbilt's Ivelin Georgiev, PhD, has received a three-year, $750,000 award from The G. Harold and Leila Y. Mathers Foundation of Rye Brook, New York, to support research aimed at rapidly identifying potent, disease-fighting antibodies.
Technique hastens COVID-19 antibody discovery
Mar. 10, 2022—Optimization of a technique developed at Vanderbilt University Medical Center enables rapid and efficient identification of neutralizing monoclonal antibodies against the virus that causes COVID-19.
“Ultra-potent” antibody against COVID-19 variants isolated at VUMC
Sep. 22, 2021—A technology developed at Vanderbilt has led to the discovery of an “ultra-potent” monoclonal antibody against multiple variants of SARS-CoV-2, the virus responsible for COVID-19, including the delta variant.
Grant helps expand VI4’s Artist-in-Residence program
Oct. 29, 2020—An innovative Vanderbilt program that brings together scientists and artists with the shared goal of scientific communication is set to expand with support from a three-year grant from the Burroughs Wellcome Fund.
Two VUMC researchers named 2020 Chancellor Faculty Fellows
Jun. 23, 2020—Two Vanderbilt University Medical Center researchers -- Jennifer (Piper) Below, PhD, associate professor of Medicine, and Ivelin Georgiev, PhD, associate professor of Pathology, Microbiology and Immunology -- have been selected for the 2020 cohort of Chancellor Faculty Fellows at Vanderbilt University.
New tool may speed antibody, vaccine research
Dec. 12, 2019— by Allison Whitten The antibody discovery and vaccine development research fields may be on the verge of rapidly expanding with data that previously took decades to acquire, thanks to LIBRA-seq, a new tool developed by Vanderbilt University researchers and their colleagues. Currently, due to technological constraints, it can take up to a year to...
A “public” target for HIV
Jun. 8, 2018—Common sequences of antibodies against HIV may be key to developing a successful vaccine strategy for the virus.